



STUDY PROTOCOL

A home-based comprehensive care model in patients with Multiple Sclerosis: A study pre-protocol [version 1; referees: 2 approved]

Lufei Young¹, Kathleen Healey², Mary Charlton³, Kendra Schmid⁴, Rana Zabad², Rebecca Wester⁵

¹College of Nursing, University of Nebraska Medical Center, Lincoln, Nebraska, USA

²Multiple Sclerosis Program, Department of Neurological Sciences, College of Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA

³Department of Epidemiology, College of Public Health, University of Iowa, Iowa City, Iowa, USA

⁴Department of Biostatistics, College of Public Health, University of Nebraska Medical Center, Omaha, Nebraska, USA

⁵Department of Family Medicine, College of Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA

v1 First published: 18 Sep 2015, 4:872 (doi: [10.12688/f1000research.7040.1](https://doi.org/10.12688/f1000research.7040.1))
 Latest published: 18 Sep 2015, 4:872 (doi: [10.12688/f1000research.7040.1](https://doi.org/10.12688/f1000research.7040.1))

Abstract

Background Disability is prevalent in individuals with multiple sclerosis (MS), leading to difficulty in care access, significant caregiver burden, immense challenges in self-care and great societal burden. Without highly coordinated, competent and accessible care, individuals living with progressive MS experience psychological distress, poor quality of life, suffer from life-threatening complications, and have frequent but avoidable healthcare utilizations. Unfortunately, current healthcare delivery models present severe limitations in providing easily accessible, patient-centered, coordinated comprehensive care to those with progressive MS. We propose a home-based comprehensive care model (MAHA) to address the unmet needs, challenges, and avoidable complications in individuals with progressive MS with disabling disease.

Objective The article aims to describe the study design and methods used to implement and evaluate the proposed intervention.

Method The study will use a randomized controlled design to evaluate the feasibility of providing a 24-month, home-based, patient-centered comprehensive care program to improve quality of life, reduce complications and healthcare utilizations overtime (quarterly) for 24 months. A transdisciplinary team led by a MS-Comprehensivist will carry out this project. Fifty MS patients will be randomly assigned to the intervention and usual care program using block randomization procedures. We hypothesize that patients in the intervention group will have fewer complications, higher quality of life, greater satisfaction with care, and reduced healthcare utilization. The proposed project is also expected to be financially sustainable in fee-for-service models but best suited for and gain financial success in valued-based care systems.

Discussion This is the first study to examine the feasibility and effectiveness of a home-based comprehensive care management program in MS patients living with progressive disability. If successful, it will have far-reaching implications in research, education and practice in terms of providing high quality but affordable care to population living with severe complex, disabling conditions.

Open Peer Review

Referee Status:

	Invited Referees	
	1	2
version 1 published 18 Sep 2015	report	report
1 Anisha Doshi , University College London UK, Jeremy Chataway , University College London UK		
2 M. Rashad Massoud , University Research Co LLC USA, Amanda Ottosson , University Research Co LLC USA		

Discuss this article

Comments (0)

Corresponding author: Lufei Young (lyoun1@unmc.edu)

How to cite this article: Young L, Healey K, Charlton M *et al.* **A home-based comprehensive care model in patients with Multiple Sclerosis: A study pre-protocol [version 1; referees: 2 approved]** *F1000Research* 2015, **4**:872 (doi: [10.12688/f1000research.7040.1](https://doi.org/10.12688/f1000research.7040.1))

Copyright: © 2015 Young L *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution Licence](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Grant information: The author(s) declared that no grants were involved in supporting this work.

Competing interests: No competing interests were disclosed.

First published: 18 Sep 2015, **4**:872 (doi: [10.12688/f1000research.7040.1](https://doi.org/10.12688/f1000research.7040.1))

Background

While great strides have been made in the treatment of relapsing forms of multiple sclerosis (MS), many individuals have or will enter a progressive phase of this disease. This phase of disease is dynamic, highly complex and disabling, which presents extensive challenges in all aspects of care delivery^{1,2}. The progressive phase of MS meets criteria for the description of “a consuming illness” outlined by the Patient-Centered Medical Home Model (PCMH)³. Specific problems and rate of progression vary, but many will have dysfunction in gait^{4,5}, movement of extremities⁴, bladder and bowel function^{6,7}, speech and swallowing⁸, and respiratory musculature^{9,10}. Over half will have physical pain¹¹, generally related to neuropathy and/or spasticity¹². Cognitive dysfunction¹³ and depressive mood disorders^{14–17} are prevalent. Family members are also likely to suffer from caregiver burden¹⁸, mood disorders¹⁹ and strain on their own health¹⁸. As the disease progresses, a significant proportion of patients will need assistive devices, including power mobility, urinary catheters, gastric tubes, hospital beds, home modifications, and other devices^{1,2}. Complications can be life threatening, including falls^{20,21}, urinary tract infections (UTIs)²², respiratory conditions (pneumonia and influenza)^{23,24}, and pressure ulcers²¹. Consequently, patients’ health related quality of life decreases substantially as disability ensues²⁵. The MS Society’s White Paper captures the cry of those with progressive MS, who feel “disconnected,” “underserved,” “isolated,” “forgotten,” and “overwhelmed”²⁶. Patients ultimately face the loss of independence in virtually all aspects of life. Still, families desire to keep their loved one at home when possible but acknowledge the overwhelming impact of the disease on the entire family²⁷. Moreover, due to the limitations in mobility, cognition and communication, access to care is highly challenging^{28,29}. As a result, patients living with progressive phase MS have numerous complex and dynamic healthcare needs that require a range of primary care, specialty, multidisciplinary, and community resources for a long period of time (their life expectancy)^{30,31}. However, the current care delivery and payment systems contribute barriers and challenges in providing comprehensive coordinated care³², leading to unnecessary healthcare utilization and delayed effective treatments³³. Without the comprehensive disease management by a designated provider, the quality of care received is often suboptimal or poor due to the fragmented care system in which the acute care based providers are unfamiliar with patients’ needs, have little knowledge and experience caring for patients with MS³⁴. The combination of the current ambulatory care system utilizes a fee-for-service payment model combined with shortage of MS care specialists leaves no time to address complex chronic care issues or advance care planning^{35–37}.

To address these problems and gaps in inadequately caring for patients living with progressive MS, we propose a home-based, patient-centered, comprehensive care management program led by a ‘MS-Comprehensivist’. The program is designed to provide a full range of medical and social services for patients and their caregivers, including a transdisciplinary team of primary care providers, specialists, care managers, rehabilitative, social home health, and personal care services. The MS-Comprehensivist who is an advance practice nurse specialized in MS care is responsible to 1) make regular house calls to address patients/family specific needs, 2) coordinate the care with the primary and specialty providers,

3) identify and mobilize other community resources, and 4) provide staff training and patient education in co-managing the complex complications and symptoms. This program, referred to as **M**ultiple Sclerosis **A**t **H**ome **A**ccess (MAHA), incorporates core principles of the chronic care and patient-centered medical home models. The purpose of the proposed study is to examine the feasibility (e.g., acceptability, utility, implementation, financial sustainability, adaptation and integration)³⁸ and effect of the MAHA model on patient-centered outcomes (i.e., complications, quality of life, satisfaction) and health care utilization outcomes (i.e., unplanned hospitalization and ED visits). The following specific aims were designed to achieve this purpose.

Specific Aim 1: To evaluate the effect of the MAHA model on 1) the numbers of complications; 2) patients’ quality of life; and 3) patients’ satisfaction over time (baseline and quarterly).

Specific Aim 2: To evaluate the effect of the MAHA model on 1) the numbers of emergency room (ER) visits, and 2) the numbers of unplanned hospitalizations.

Specific Aim 3: To evaluate the feasibility of the MAHA model.

- 1) Acceptability by assessing patient and family experience with the program, as well as provider satisfaction
- 2) Utility by examining the actual use of the program and number of referral received by other providers
- 3) Implementation by evaluating the amount and type of resources needed to implement and factors affecting implementation;
- 4) Adaptation by evaluating the selected elements of the program delivered by tele-health is as effective as face-to-face format.
- 5) Financial sustainability and cost saving by comparing the estimated total cost of the program and financial compensation from payers.

Conceptual framework

The conceptual framework supporting the MAHA program (**Figure 1**) is designed based on the core elements in Wagner’s Chronic Care Model (CCM) and Donabedian’s Structure-Process-Outcome (SPO) model³⁹. First, based on Wagner’s CCM, the MAHA model emphasizes the re-design of existing community and healthcare systems to be patient-centered⁴⁰. From the patient-provider level, the unique MAHA model again is structured surrounding patients’ needs with the following key components: 1) the productive interaction between informed, activated patient/family and the MAHA team; 2) a transdisciplinary team led by an MS-Comprehensivist who is an advance practice nurse with expertise in MS care, chronic disease management and primary care; 3) care coordination and effective communication among care team members. As a result of re-designing care systems and processes, it is expected that patient outcomes (e.g. complication, quality of life and satisfaction of care) are improved, leading to reduced unplanned healthcare utilizations.




Figure 1. MAHA Model Framework adapted from Wagner's Chronic Care Model.

Besides its function as an acronym for **M**ultiple Sclerosis **A**t **H**ome **A**ccess, the term **MAHA** is derived from its city of origin in Omaha, Nebraska, which was settled by Native Americans of the Omaha tribe. In their language, Omaha means “against the wind or current,” which reflects American Indians survival experience from severe weather, disease and scarcity⁴¹. While caring for and supporting those MS patients with profound disabling and chronic, complex complications, the caregivers and providers often feel overwhelmed by the environmental barriers, much like the Omaha tribe must have felt centuries ago. Consistent with the core values of these original settlers (earth and sky)⁴¹, we honor holistic care which includes evidence-based medicine (earth) and equally holistic care including social, emotional, and spiritual applications (sky).

Methods

Study design

The study is a prospective, two-group, randomized experimental design with nine data collection points (baseline and every three months). MS patients recruited from a neurology clinic will be randomized into two groups: the intervention or usual care group. The usual care group receives the current standardized MS care, while the intervention group receives usual care plus 24-months of the MAHA intervention provided by a transdisciplinary team led by a MS-Comprehensivist. The usual care group will receive the intervention at the end of the 24-month period if the intervention is found to be effective by our a priori criteria. The study is subject to review and approval by the University of Nebraska Medical Center Institutional Review Board (IRB) and informed consent will be obtained from all participants prior to the study.

Study settings

Potential subjects will be identified and recruited from the University of Nebraska Medical Center (UNMC) neurology clinic, where the principle investigator, who has ethical access at the clinic site, will be responsible for identifying the potential participants, screening for eligibility and referring eligible subjects for recruitment.

Study participants

Inclusion criteria. Patients are eligible for the study if they: 1) have a diagnosis of progressive MS; 2) receive a Kurtzke Expanded Disability Status Scale (EDSS) score ≥ 6.5 (requires bilateral assist for ambulation and cannot walk > 120 meters; http://www.nationalmssociety.org/NationalMSSociety/media/MSNationalFiles/Brochures/10-2-3-29-EDSS_Form.pdf); and 3) have a home residence located within 60 miles of the Omaha metropolitan area.

Sample size

The sample size estimation is computed based on **Specific Aim 1**: the increased score of quality of life (QoL) and **Specific Aim 2**: the reduced number of unplanned healthcare utilizations associated with complications. An estimated 50 patients per group will provide 80% power to detect a 5-point difference [Usual Care mean (SD): 45(8.6), MAHA mean (SD) 50(8.6)] between groups in the SF-36 Mental Health Component Score QoL. This sample size also provides 80% power at a 5% significance level to detect a 34% reduction in unplanned visits/admits (from 2.5 per person per year to 1.65, using the Poisson distribution, which is most appropriate for count/rate data). These are feasible and clinically important differences. Based on our preliminary analyses, 125 patients are

currently expected to meet these criteria. Furthermore, based on our previous patient survey results, a high proportion of patients (~80% or n = 100) have expressed a genuine interest in participating in MS research for the benefit of others with this disabling disease. Furthermore, we estimate 50 patients will be a reasonable panel size for the MS-Comprehensivist or care team leader (CTL) in the MAHA model (unpublished report).

MAHA intervention

The MAHA model is a patient- and family-centered system in which care is tailored around the complex, chronic needs of those with progressive disabling MS. The intervention program is designed to address a fundamental question: “how will this affect the patient and/or family?” The majority of care and medical services will be provided at home, thus avoiding frequent and cumbersome clinic visits. The intervention strategies were developed based on the frequent requests and suggestions from patients with progressive MS, along with caregivers and providers experiencing daily struggles with fragmented care. Furthermore, the model is also supported by initiatives from the health policy literature developed by the National Multiple Sclerosis Society (NMSS), emphasizing the need for home- and community-based services (<http://www.nationalmssociety.org/Treating-MS/Comprehensive-Care>).

MAHA Team Structure. The intervention will be delivered by a transdisciplinary team led by a MS-Comprehensivist, also referred to as Care Team Leader (CTL). The care provided is comprehensive and holistic, addressing patient/family physical, emotional and spiritual, and social needs. The transdisciplinary team includes the core team partners and “neighbors and best friends” (Figure 2).

The CTL role will be filled by a nurse practitioner (NP) with specialty training in MS and extensive experience managing patients with chronic illness. The core team partners include the CTL, MS neurologist, primary care provider (PCP), and selected home health agencies. To address MS patients’ complex needs and reduce unplanned healthcare services, the CTL will closely collaborate with patients and family, the MS neurologist and the PCP to develop patient-centered care plans and goals, and to co-manage symptoms and complications. The selected home health agencies will provide nursing and personal care staff, physical and occupational therapists (PT/OT), and social work services. They are responsible for carrying out the care plan and conducting collaborative, on-going evaluation of the care plan with the CTL. Given MS patients’ limitations in mobility, PT/OTs will also be involved in plans of care to facilitate the restoration and maintenance of function oriented toward activities of daily living (ADLs). PTs from the home health agencies will be trained by physical therapists who have extensive experience in the education and care of MS patients. “Neighbors & Best Friends” represent subspecialty providers and community resources. The “neighbors”, or subspecialty providers (e.g., urologist, rehabilitative professionals, palliative care specialist, ophthalmologist, wound care specialist, etc.) provide consultation services and advise the CTL in preventative and treatment strategies for common complications or issues not responsive to standard strategies. The “Best Friends”, include community resources, including clergy, respite services, the MS Society, League of Human Dignity, and Office on Aging, among others.

MAHA Team Processes (10 C’s). The MS-Comprehensivist or CTL will be responsible to: 1) provide regular and frequent visits




Figure 2. MAHA Model.

to patients' homes using a pre-planned schedule based on each individual's care needs; 2) coordinate patients' care by collaborating and communicating closely with the core team partners, and "neighbors and best friends"; and 3) train the home health staff in the specialty care of MS patients. In the process of care, the MAHA model stresses patient/family engagement (i.e., informed and activated) and productive interaction between patients and providers through ten fundamental elements (10 Cs; [Figure 3](#)).

Data collection, instruments and sources of data

Key data collection instruments, assessments, and measures are summarized in [Table 1](#). This information will be collected from three data sources: 1) patient reports to CRC personnel, 2) patient reports to the CTL or other MAHA team member at each home visit, and 3) medical record review.

Data analysis

Specific Aim 1 and 2. The data analysis will follow the intention-to-treat (ITT) protocol. To ensure groups are comparable, descriptive analyses, including t-tests and Chi-square tests will be conducted to compare the characteristics of each group at baseline. The occurrence of complications and other self-reported measures, such as ADLs, Multiple Sclerosis QoL Inventory (MSQLI), CSQ-8, and Caregiver Burden Inventory (CBI) will be compared between groups using a linear mixed model to account for the repeated measurements over time and adjust for baseline scores of the respective measures. To determine if differences exist between groups after adjusting for potential confounding variables, such as age, gender, comorbidity, etc. or imbalances between groups,

unplanned healthcare utilization (i.e., visits/admissions) will be analyzed using Poisson regression models. The proportion of any versus no use of each health service (e.g., proportion with any inpatient admissions versus the proportion with no admissions) will be compared between groups using Chi-square tests. The time-by-group interaction will be investigated to determine if any changes over time are consistent between groups.

Specific Aim 3. To assess the acceptability, utility, implementation and adaptation of the program, we will create a toolkit that comprehensively describes our program structure, processes, patients/provider/system outcomes, as well as lessons learned. This toolkit will serve to evaluate the MAHA program and identify system-, provider-, and patient-levels of barriers and facilitators. To evaluate financial sustainability, we will specifically track the Current Procedural Terminology (CPT) codes for evaluation and management visits (clinic and home visits), care coordination, and care plan oversight. Reimbursement amounts associated with these codes will be summed for each study group at six and 12 months. T-tests and log transformed linear regression models will be used to compare total reimbursement amounts between groups. Also, staffing and associated salary estimates will be computed based on home visit time logs maintained by the MAHA team members, on-call activity logs, and number of home visits in the intervention group. We will project the necessary percent FTE and salary to execute the intervention model based on a range of panel sizes (e.g., 25, 50, 100 patients) per MS-Comprehensivist/CTL. The ratio of total salary costs-to-reimbursement amount for a given number of patients will be calculated for each group and compared using t-tests.

- | |
|--|
| <ol style="list-style-type: none"> 1. Cooperation. Full support at the organizational, provider and patient levels. 2. Comprehensiveness. A full spectrum services ranging from preventive to palliative/hospice care, addressing all aspects of needs (e.g., physical, emotional, social, and spiritual). 3. Caring and Compassion ensures that goals and strategies of care are consistent with patients' wishes, and that patients can make informed decisions on care directives with their decisions valued and respected. 4. Communication On-going communication to keep everyone on the "same page", 5. Credibility and Consistency. The development of intervention strategies that are protocol-driven, evidence-based, and prevention-focused. 6. Coordination Timely communication and integrated care plan to facilitate care coordination at care transitional point. 7. Continuity. The development of sustained and consistent patient-provider relationships and detained documentation to ensure the continuity of care. 8. Competency Continuing education and training to promote competency in managing MS and its complications among team members and patient/family. 9. Continuous Quality Improvement. Systematic evaluation to ensure safe and high-quality care. 10. Cost Awareness. Tracking time, resource utilization and reimbursement to improve efficiency and evaluate the long-term financial viability of the model. |
|--|

Figure 3. Ten fundamental elements guiding the care process.

Table 1. Study measures.

Data Collection Instrument/Assessment		Method, Location, Data Source	Measure Timeline (in months)									
			BL*	3	6	9	12	15	18	21	24	
Kurtzke Expanded Disability Scale (EDSS)		Neurologist/CTL to assess in person	X				X					X
PATIENT REPORTED MEASURES												
-Demographics		CRC to collect at baseline visit and via mail/phone	X									
-Functional activity of daily livings (ADLs) (Barthel) ⁴²			X	X	X	X	X	X	X	X	X	X
-Multiple Sclerosis QoL Inventory (MSQLI) ⁴³			X				X					X
-Novak Caregiver Burden Inventory (CBI) ⁴⁴			X	X	X	X	X	X	X	X	X	X
-Client Satisfaction Questionnaire (CSQ-8) ⁴⁵			X		X		X		X			X
POTENTIAL COMPLICATONS												
-Pneumonia	-Falls	CRC to collect at baseline visit, via mail/phone and from medical record review. Providers assess during in-person visits	X	X	X	X	X	X	X	X	X	X
-Urinary Tract Infection (UTI)	-Pressure Ulcer											
HEALTH SERVICES USE												
<u>Emergency Room (ER)</u> -Unplanned (acute)	<u>Inpatient Admissions</u> -Planned (elective) -Unplanned (acute) -Length of Stay	CRC to collect at baseline visit and via mail/phone. Providers assess during in-person visits. Data are retrieved from medical record.	X	X	X	X	X	X	X	X	X	X
CPT Codes and Reimbursement Amounts		UNMC Neurology Clinic Database	X		X		X		X		X	
MAHA RESOURCE INTENSITY												
-Home visit time logs -On-call activity logs -Coordination care management activities		MAHA staff to document after each home visit and on-call activity	X	X	X	X	X	X	X	X	X	

*Baseline questionnaires will be performed at the baseline clinic visit

Discussion

The study is highly relevant to MS patients overwhelmed by the challenges of accessing healthcare and the myriad of complications related to such a progressive, disabling disease. The purpose is to examine the feasibility and effectiveness of a home-based, patient-centered, comprehensive care model on patient reported and healthcare utilization outcomes. Although the tools, expertise, and strategies to prevent many of these complications and to improve quality of life exist and prove to be effective, their use and implementation is hindered by a siloed system, fragmented care processes, and an inappropriate volume-based payment system. The proposed study is designed to evaluate an innovative model to meet the complex needs and overcome the self-care challenges of those MS patients in a progressive, disabling stage of disease.

Implication to Practice: The study findings and all project materials will assist other institutions and providers in adapting the MAHA model to manage MS and other populations living with chronic complex conditions. In addition, the study findings may inform NMSS to develop and/or update guidelines in managing MS patients in progressive stage, leading to the improved care and prolonged lives of MS patients.

Implication to Education: The toolkits and manuals we developed for patient/provider education could be integrated into the curriculum in various healthcare professional programs and modified to be continuing education packets for clinicians.

If proven successful, we will further adapt the model components and intervention strategies to be delivered via telehealth to reach rural/remote populations facing significant challenges in accessing care. Based on our preliminary analysis and the expertise of our team, we believe the MAHA intervention will be the missing ingredient for mitigating the challenges in managing populations living with chronic and complex illness. The long-term goal of this study is to conduct a larger scale study and create a template of chronic complex disease management to be expanded and disseminated in managing all population living with disabling and consuming conditions.

Author contributions

All authors contributed to the development of this study protocol. Dr. Young prepared the manuscript. Dr. Healey and Dr. Charlton conceived and designed the intervention and the underlying

conceptual framework. Dr. Healey, Dr Zabad, and Dr. Wester did preliminary study to gather feasibility evidence of this study protocol. Dr Schmid and Dr. Charlton assisted study design, the development of outcome measures and data management plan. All authors contributed to revising the manuscript and have agreed to the final version of this protocol.

Competing interests

No competing interests were disclosed.

Grant information

The author(s) declared that no grants were involved in supporting this work.

References

- Fraser R, Ehde D, Amtmann D, *et al.*: **Self-management for people with multiple sclerosis: report from the first international consensus conference, November 15, 2010.** *Int J MS Care.* 2013; **15**(2): 99–106.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Schapiro RT: **The symptomatic management of multiple sclerosis.** *Ann Indian Acad Neurol.* 2009; **12**(4): 291–295.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- American College of Physicians. **The patient centered medical home neighbor: The interface of the patient-centered home with Specialty/Subspecialty practices.** *American College of Physicians Policy Paper.* 2010.
[Reference Source](#)
- Minden SL, Frankel D, Hadden L, *et al.*: **The Sonya Slifka Longitudinal Multiple Sclerosis Study: methods and sample characteristics.** *Mult Scler.* 2006; **12**(1): 24–38.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Pike J, Jones E, Rajagopalan K, *et al.*: **Social and economic burden of walking and mobility problems in multiple sclerosis.** *BMC Neurol.* 2012; **12**: 94.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Chia YW, Fowler CJ, Kamm MA, *et al.*: **Prevalence of bowel dysfunction in patients with multiple sclerosis and bladder dysfunction.** *J Neurol.* 1995; **242**(2): 105–108.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Nortvedt MW, Riise T, Frugård J, *et al.*: **Prevalence of bladder, bowel and sexual problems among multiple sclerosis patients two to five years after diagnosis.** *Mult Scler.* 2007; **13**(1): 106–112.
[PubMed Abstract](#) | [Publisher Full Text](#)
- De Pauw A, Dejaeger E, D'hooghe B, *et al.*: **Dysphagia in multiple sclerosis.** *Clin Neurol Neurosurg.* 2002; **104**(4): 345–351.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Gosselin R, Kovacs L, Decramer M: **Respiratory muscle involvement in multiple sclerosis.** *Eur Respir J.* 1999; **13**(2): 449–454.
[PubMed Abstract](#)
- Srouf N, LeBlanc C, King J, *et al.*: **Lung volume recruitment in multiple sclerosis.** *PLoS One.* 2013; **8**(1): e56676.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Minden SL, Frankel D, Hadden LS, *et al.*: **Disability in elderly people with multiple sclerosis: An analysis of baseline data from the Sonya Slifka Longitudinal Multiple Sclerosis Study.** *NeuroRehabilitation.* 2004; **19**(1): 55–67.
[PubMed Abstract](#)
- Foley PL, Vesterinen HM, Laird BJ, *et al.*: **Prevalence and natural history of pain in adults with multiple sclerosis: Systematic review and meta-analysis.** *Pain.* 2013; **154**(5): 632–642.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Rao SM, Leo GJ, Bernardin L, *et al.*: **Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction.** *Neurology.* 1991; **41**(5): 685–691.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Chwastiak L, Ehde DM, Gibbons LE, *et al.*: **Depressive symptoms and severity of illness in multiple sclerosis: epidemiologic study of a large community sample.** *Am J Psychiatry.* 2002; **159**(11): 1862–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Wood B, van der Mei IA, Ponsonby AL, *et al.*: **Prevalence and concurrence of anxiety, depression and fatigue over time in multiple sclerosis.** *Mult Scler.* 2013; **19**(2): 217–224.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Marrie RA, Horwitz R, Cutter G, *et al.*: **The burden of mental comorbidity in multiple sclerosis: frequent, underdiagnosed, and undertreated.** *Mult Scler.* 2009; **15**(3): 385–392.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Korostil M, Feinstein A: **Anxiety disorders and their clinical correlates in multiple sclerosis patients.** *Mult Scler.* 2007; **13**(1): 67–72.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Acaster S, Perard R, Chauhan D, *et al.*: **A forgotten aspect of the NICE reference case: an observational study of the health related quality of life impact on caregivers of people with multiple sclerosis.** *BMC Health Serv Res.* 2013; **13**: 346.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Lehan T, Arango-Lasprilla JC, Macias MA, *et al.*: **Distress associated with patients' symptoms and depression in a sample of Mexican caregivers of individuals with MS.** *Rehabil Psychol.* 2012; **57**(4): 301–307.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Gunn H, Creanor S, Haas B, *et al.*: **Frequency, characteristics, and consequences of falls in multiple sclerosis: findings from a cohort study.** *Arch Phys Med Rehabil.* 2014; **95**(3): 538–45.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Redelings MD, McCoy L, Sorvillo F: **Multiple sclerosis mortality and patterns of comorbidity in the united states from 1990 to 2001.** *Neuroepidemiology.* 2006; **26**(2): 102–107.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Manack A, Motsko SP, Haag-Molkenteller C, *et al.*: **Epidemiology and healthcare utilization of neurogenic bladder patients in a US claims database.** *NeuroUrol Urodyn.* 2011; **30**(3): 395–401.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Sumelahti ML, Hakama M, Elovaara I, *et al.*: **Causes of death among patients with multiple sclerosis.** *Mult Scler.* 2010; **16**(12): 1437–1442.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Hirst C, Swingler R, Compston DA, *et al.*: **Survival and cause of death in multiple sclerosis: a prospective population-based study.** *J Neurol Neurosurg Psychiatry.* 2008; **79**(9): 1016–1021.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Naci H, Fleurence R, Birt J, *et al.*: **The impact of increasing neurological disability of multiple sclerosis on health utilities: a systematic review of the literature.** *J Med Econ.* 2010; **13**(1): 78–89.
[PubMed Abstract](#) | [Publisher Full Text](#)
- MS Society: **Strategic response white paper 2011-2015.**
[Reference Source](#)
- Meca J, Del Mar Mendibe Bilbao M: **Burden of multiple sclerosis on caregivers and patients and degree of satisfaction with current treatment: The MS-feeling study (P3. 148).** *Neurology.* 2014; **82**(10 Supplement): P3.148.
[Reference Source](#)
- Thompson AE: **JAMA patient page. The Americans with Disabilities Act.** *JAMA.* 2015; **313**(22): 2296.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Iezzoni LI: **Eliminating health and health care disparities among the growing population of people with disabilities.** *Health Aff (Millwood).* 2011; **30**(10): 1947–1954.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Skovgaard L, Bjerre L, Haahr N, *et al.*: **An investigation of multidisciplinary complex health care interventions--steps towards an integrative treatment model in the rehabilitation of people with multiple sclerosis.** *BMC Complement Altern Med.* 2012; **12**: 50.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Nancy Holland Ed D R: **Comprehensive nursing care in multiple sclerosis.** Springer Publishing Company; 2010.
[Reference Source](#)
- Institute of Medicine (US) Committee on Quality of Health Care in America. **Crossing the Quality Chasm: A New Health System for the 21st Century.** Washington (DC): National Academies Press (US); 2001.
[PubMed Abstract](#)
- Nusrat S, Levinthal D, Bielefeldt K: **Hospitalization rates and discharge status in multiple sclerosis.** *Mult Scler Int.* 2013; **2013**: 436929.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Wallin MT: **Integrated multiple sclerosis care: new approaches and paradigm shifts.** *J Rehabil Res Dev.* 2010; **47**(5): ix–xiv.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Dall TM, Storm MV, Chakrabarti R, *et al.*: **Supply and demand analysis of the current and future US neurology workforce.** *Neurology.* 2013; **81**(5): 470–478.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

36. Coleman K, Austin BT, Brach C, *et al.*: **Evidence on the Chronic Care Model in the new millennium.** *Health Aff (Millwood)*. 2009; **28**(1): 75–85.
[PubMed Abstract](#) | [Publisher Full Text](#)
37. Bodenheimer T, Chen E, Bennett HD: **Confronting the growing burden of chronic disease: can the U.S. health care workforce do the job?** *Health Aff (Millwood)*. 2009; **28**(1): 64–74.
[PubMed Abstract](#) | [Publisher Full Text](#)
38. Bowen DJ, Kreuter M, Spring B, *et al.*: **How we design feasibility studies.** *Am J Prev Med*. 2009; **36**(5): 452–457.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
39. Donabedian A: **The quality of care. How can it be assessed?** *JAMA*. 1988; **260**(12): 1743–1748.
[PubMed Abstract](#) | [Publisher Full Text](#)
40. Wielawski IM: **Improving chronic illness care.** Birmingham: HSMC, University of Birmingham and NHS Institute for Innovation and Improvement. 2006.
[Reference Source](#)
41. Swanton JR: **The Indian tribes of North America.** Genealogical Publishing Com; 1952.
[Reference Source](#)
42. Mahoney FI, Barthel DW: **Functional evaluation: The barthel index.** *Md State Med J*. 1965; **14**: 61–65.
[PubMed Abstract](#)
43. Cella DF, Dineen K, Arnason B, *et al.*: **Validation of the functional assessment of multiple sclerosis quality of life instrument.** *Neurology*. 1996; **47**(1): 129–139.
[PubMed Abstract](#) | [Publisher Full Text](#)
44. Novak M, Guest C: **Application of a multidimensional caregiver burden inventory.** *Gerontologist*. 1989; **29**(6): 798–803.
[PubMed Abstract](#) | [Publisher Full Text](#)
45. Larsen DL, Attkisson CC, Hargreaves WA, *et al.*: **Assessment of client/patient satisfaction: development of a general scale.** *Eval Program Plann*. 1979; **2**(3): 197–207.
[PubMed Abstract](#) | [Publisher Full Text](#)

Open Peer Review

Current Referee Status:



Version 1

Referee Report 02 December 2015

doi:10.5256/f1000research.7578.r11257



M. Rashad Massoud¹, Amanda Ottosson²

¹ Department of Public Health, University Research Co LLC, Bethesda, MD, USA

² University Research Co LLC, Bethesda, MD, USA

This is an important study and is very well designed. The study has a clear objectives and aims to overcome four challenges in care for patients with multiple sclerosis. The objective of the article is to describe the study design and methods that were used to implement and evaluate the use of the home-based comprehensive care model (MAHA) to overcome the following four challenges:

1. Difficulty in care access
2. Caregiver burden
3. Self-care challenges
4. Societal burden

The intervention uses the MAHA and Chronic Care Model. 50 patients will be randomly assigned to receive the intervention or usual care. The authors hypothesized that there would be fewer complications, higher quality of life, greater satisfaction with care, and reduced healthcare utilization to patients who received the intervention.

The authors described the theory of change well and it is plausible. We have one suggestion to the investigation. If the objective is to improve care in patients with progressive multiple sclerosis, then iterative testing of changes, and learning from these tests, may be more valuable than testing the effectiveness of a "set intervention".

This type of inquiry might lend itself to an ongoing type of treatment and modifications of the implementation of the intervention as opposed to an endline assessment. This would allow for a deeper understanding of the elements of the intervention that did and did not work. More importantly, one could look into why and how they worked or did not.

The title and the abstract are appropriate for the article. We look forward to seeing the results of the study.

We have read this submission. We believe that we have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Competing Interests: No competing interests were disclosed.

Referee Report 23 October 2015

doi:10.5256/f1000research.7578.r10803



Anisha Doshi¹, Jeremy Chataway²

¹ The Queen Square Multiple Sclerosis Centre, University College London, London, UK

² Queen Square Multiple Sclerosis Centre, University College London, London, UK

This article aims to define a new study pre-protocol examining the efficacy of a home-based comprehensive care model, Multiple Sclerosis At Home Access (MAHA), in patients with Progressive Multiple Sclerosis (MS) versus the current healthcare delivery models. In particular the study pre-protocol describes a prospective 24 month block randomised controlled model using an estimated cohort of 50 patients in each arm with the following inclusion criteria; Progressive MS, Kurtze EDSS above or equal to 6.5, and live in a residence within 60 miles of the Omaha metropolitan area. The study is subject to review and approval by the University of Nebraska Medical Center Institutional Review Board (IRB). It would be useful to outline the currently available comprehensive care model. The proposed study measures and data analysis should be sufficient in answering the outcome measures and specific study aims.

In our opinion, this study pre-protocol, if approved, will add to the already established data with regard to comprehensive care models, and in particular may be of relevance to those focussing on patients with significant disability due MS as well as to other conditions.

References:

PMID [23692584](#)

PMID [22247419](#)

PMID [20047364](#)

We have read this submission. We believe that we have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Competing Interests: No competing interests were disclosed.
